NASDAQ:CUR Neuralstem (CUR) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free CUR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.81▼$6.5050-Day Range$0.67▼$1.5252-Week Range$1.10▼$13.78Volume217,635 shsAverage Volume236,278 shsMarket Capitalization$12.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Neuralstem alerts: Email Address Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Neuralstem Stock (NASDAQ:CUR)Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.Read More Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. CUR Stock News HeadlinesNovember 25, 2023 | lse.co.ukAguas Da Curia Share Price (CUR.LS)August 22, 2023 | seekingalpha.comXAUUSD:CUR Gold Spot PriceApril 29, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”July 20, 2023 | thestreet.com4 Biotech Stocks Under $10 Moving HigherJune 28, 2023 | seekingalpha.comXPTUSD:CUR Platinum Spot PriceMay 16, 2023 | seekingalpha.comXAUUSD:CUROctober 20, 2022 | marketscreener.comNovAccess Global : Announces Fireside Chat with Board Member Perspectives - Marketscreener.comOctober 12, 2022 | news.yahoo.comAnti-inflammatory compound supercharges stem cell stroke treatment - Yahoo NewsApril 29, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”October 11, 2022 | businessinsider.comBest microscope photos of 2022 reveal stunning hidden world around us - Business InsiderOctober 11, 2022 | benzinga.comStem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - BenzingaOctober 6, 2022 | globenewswire.comAruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit - GlobeNewswireSeptember 16, 2022 | streetinsider.comBOLDEN THERAPEUTICS RECEIVES $406,466 SBIR GRANT FROM THE NATIONAL INSTITUTE ON AGING TO SUPPORT DEVELOPMENT OF ANTISENSE OLIGONUCLEOTIDES TO PROMOTE NEUROGENESIS - StreetInsider.comSeptember 2, 2022 | prnewswire.comBGI-led Research Builds the World's First Spatiotemporal Map of Brain Regeneration - PR NewswireAugust 23, 2022 | globenewswire.comGlobal Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight - GlobeNewswireAugust 23, 2022 | newsweek.comHow Scientists Successfully Reversed Alzheimer's in Mice - NewsweekAugust 22, 2022 | techcrunch.comDioseve wants to help infertile people with tech that grows egg cells - TechCrunchAugust 12, 2022 | finance.yahoo.comThe Global Stem Cell Manufacturing Market grew USD 4,378.00 million by 2027, at a CAGR of 12.23%. - Yahoo FinanceAugust 12, 2022 | globenewswire.comThe Global Stem Cell Manufacturing Market grew USD 4,378.00 - GlobeNewswireAugust 4, 2022 | finance.yahoo.comCalidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma - Yahoo FinanceAugust 2, 2022 | businesswire.comCalidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma - Business WireAugust 1, 2022 | in.investing.comHow chickenpox virus is linked to onset of Alzheimer's disease - Investing.com IndiaJuly 21, 2022 | forbes.comCan Inflammation Lead To Cognitive Issues? Past Research Says 'Yes', With Implications For Covid-19 - ForbesJuly 17, 2022 | abcnews.go.comHigh-flying experiment: Do stem cells grow better in space? - ABC NewsJuly 12, 2022 | streetinsider.comjCyte Announces Appointment of Dr. Stewart Craig as Chief Technology Officer - StreetInsider.comJuly 11, 2022 | forbes.comResearch On Flies Provides Hope For Brain Repair - ForbesJuly 7, 2022 | finance.yahoo.comStem Cell Assays Market Report 2022-2027: Government Initiatives to Boost Stem Cell Research Present Opportunities - Yahoo FinanceSee More Headlines Receive CUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuralstem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2019Today4/29/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CUR CUSIPN/A CIK1357459 Webwww.neuralstem.com Phone301-366-4841FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,930,000.00 Net Margins-39,417.64% Pretax MarginN/A Return on Equity-170.51% Return on Assets-110.16% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual Sales$260,000.00 Price / Sales48.87 Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book0.91Miscellaneous Outstanding Shares2,100,000Free FloatN/AMarket Cap$12.71 million OptionableNot Optionable Beta1.81 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Kenneth C. Carter (Age 59)Exec. Chairman, CEO & Principal Financial Officer Dr. Karl Y. Johe (Age 59)Co-Founder Dr. Thomas G. Hazel Ph.D.Sr. VP of ResearchDr. David P. Recker (Age 61)Chief Medical Officer Key CompetitorsCoeptis TherapeuticsNASDAQ:COEPSenti BiosciencesNASDAQ:SNTINanoString TechnologiesNASDAQ:NSTGQInhibikase TherapeuticsNYSE:IKTBioCardiaNASDAQ:BCDAView All Competitors CUR Stock Analysis - Frequently Asked Questions How were Neuralstem's earnings last quarter? Neuralstem, Inc. (NASDAQ:CUR) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($1.45) earnings per share (EPS) for the quarter. The company earned $0.01 million during the quarter. Neuralstem had a negative trailing twelve-month return on equity of 170.51% and a negative net margin of 39,417.64%. When did Neuralstem's stock split? Shares of Neuralstem reverse split on the morning of Thursday, July 18th 2019. The 1-20 reverse split was announced on Tuesday, July 16th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 17th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Neuralstem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuralstem investors own include XOMA (XOMA), MannKind (MNKD), Cytokinetics (CYTK), Turkcell Iletisim Hizmetleri A.S. (TKC), Idera Pharmaceuticals (IDRA), ACADIA Pharmaceuticals (ACAD), Athersys (ATHX), Caladrius Biosciences (CLBS), Rexahn Pharmaceuticals (REXN) and This page (NASDAQ:CUR) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuralstem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.